KO Cancer Act

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3873 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 3873

    To increase funding for cancer research by the National Cancer 
  Institute to be more in proportion to the mortality rates of cancer.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             June 10, 2025

Mr. Fitzpatrick (for himself and Mrs. Dingell) introduced the following 
  bill; which was referred to the Committee on Appropriations, and in 
 addition to the Committee on Energy and Commerce, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL


 
    To increase funding for cancer research by the National Cancer 
  Institute to be more in proportion to the mortality rates of cancer.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Knock Out Cancer Act'' or the ``KO 
Cancer Act''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) Cancer is one of the leading causes of death in the 
        world and has touched nearly every life, either directly or 
        indirectly.
            (2) Cancer is the cause of nearly 1 out of every 4 deaths 
        in the United States, since 2000 totaling over 15 million 
        American lives.
            (3) Efforts to increase awareness of cancer symptoms among 
        patients and clinicians would lead to earlier detection and 
        improvements in survival rates.
            (4) Scientific understanding and research lead to 
        innovations in effective treatments, controls, and cures for 
        cancer.
            (5) The National Cancer Institute has been a leader in 
        finding medical breakthroughs for treatment and therapies for 
        cancer patients.
            (6) Through substantial investment in cancer research, 
        potentially even the tripling of necessary funding, the United 
        States will be best able to address the mortality rates of 
        cancer and the impacts on the patient population.

SEC. 3. INCREASING NCI BUDGET FOR CANCER RESEARCH.

    To conduct or support cancer research, there is hereby 
appropriated, for each of fiscal years 2026 through 2030, to the 
National Cancer Institute, out of amounts in the Treasury not otherwise 
appropriated, an amount that is equal to 25 percent of the total amount 
appropriated to the National Cancer Institute for fiscal year 2022, to 
remain available until expended. Amounts appropriated pursuant to the 
preceding sentence shall be in addition to amounts otherwise made 
available to the National Cancer Institute.

SEC. 4. REPORT TO CONGRESS ON CANCER DRUG SHORTAGES.

    (a) Study.--The Secretary of Health and Human Services, acting 
through the Commissioner of Food and Drugs, in collaboration with such 
other agencies as the Secretary deems necessary, shall study the 
reasons for cancer drug shortages, including--
            (1) economic reasons;
            (2) supply chain failures;
            (3) delays and other complications relating to--
                    (A) the development of cancer drugs; and
                    (B) the approval of such drugs by the Food and Drug 
                Administration; and
            (4) insufficient generic drugs and biosimilar biological 
        products.
    (b) Report.--
            (1) In general.--Not later than 1 year after the date of 
        enactment of this Act, the Secretary of Health and Human 
        Services, acting through the Commissioner of Food and Drugs, 
        shall complete the study under subsection (a) and submit a 
        report to the appropriate committees of the Congress on the 
        results of such study.
            (2) Recommendations.--The report under paragraph (1) shall 
        include recommendations for addressing the reasons for cancer 
        drug shortages.
                                 <all>